Free Trial

Marker Therapeutics (MRKR) Stock Price, News & Analysis

Marker Therapeutics logo
$1.71 -0.09 (-5.00%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$1.66 -0.04 (-2.63%)
As of 07/11/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Marker Therapeutics Stock (NASDAQ:MRKR)

Key Stats

Today's Range
$1.60
$1.82
50-Day Range
$1.10
$1.87
52-Week Range
$0.95
$5.99
Volume
169,154 shs
Average Volume
83,214 shs
Market Capitalization
$19.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.17
Consensus Rating
Strong Buy

Company Overview

Marker Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
93rd Percentile Overall Score

MRKR MarketRank™: 

Marker Therapeutics scored higher than 93% of companies evaluated by MarketBeat, and ranked 94th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Marker Therapeutics has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Marker Therapeutics has received no research coverage in the past 90 days.

  • Read more about Marker Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Marker Therapeutics are expected to decrease in the coming year, from ($0.65) to ($2.19) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Marker Therapeutics is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Marker Therapeutics is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Marker Therapeutics has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Marker Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.55% of the float of Marker Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Marker Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Marker Therapeutics has recently decreased by 29.20%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Marker Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Marker Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.55% of the float of Marker Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Marker Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Marker Therapeutics has recently decreased by 29.20%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Marker Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.00 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Marker Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    5 people have searched for MRKR on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Marker Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    14.50% of the stock of Marker Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 22.39% of the stock of Marker Therapeutics is held by institutions.

  • Read more about Marker Therapeutics' insider trading history.
Receive MRKR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRKR Stock News Headlines

Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.
Marker Therapeutics (MRKR) Receives a Buy from Canaccord Genuity
See More Headlines

MRKR Stock Analysis - Frequently Asked Questions

Marker Therapeutics' stock was trading at $3.11 at the start of the year. Since then, MRKR stock has decreased by 45.0% and is now trading at $1.71.

Marker Therapeutics, Inc. (NASDAQ:MRKR) issued its quarterly earnings results on Monday, March, 31st. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.14. The company had revenue of $1.22 million for the quarter, compared to the consensus estimate of $5.25 million. Marker Therapeutics had a negative net margin of 224.46% and a negative trailing twelve-month return on equity of 101.87%.

Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Marker Therapeutics investors own include SCYNEXIS (SCYX), Tesla (TSLA), Meta Platforms (META), Pfizer (PFE), NVIDIA (NVDA), Viking Therapeutics (VKTX) and OPKO Health (OPK).

Company Calendar

Last Earnings
3/31/2025
Today
7/12/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MRKR
CIK
1094038
Fax
N/A
Employees
60
Year Founded
2018

Price Target and Rating

High Price Target
$19.00
Low Price Target
$8.00
Potential Upside/Downside
+670.0%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.33)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$10.73 million
Net Margins
-224.46%
Pretax Margin
-223.56%
Return on Equity
-101.87%
Return on Assets
-83.02%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.79
Quick Ratio
6.79

Sales & Book Value

Annual Sales
$6.59 million
Price / Sales
2.93
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.73 per share
Price / Book
0.99

Miscellaneous

Outstanding Shares
11,310,000
Free Float
9,674,000
Market Cap
$19.34 million
Optionable
Not Optionable
Beta
1.43

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:MRKR) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners